BR112014028406A2 - derivados de pirazol e uso dos mesmos como antagonistas de lpar5. - Google Patents

derivados de pirazol e uso dos mesmos como antagonistas de lpar5.

Info

Publication number
BR112014028406A2
BR112014028406A2 BR112014028406A BR112014028406A BR112014028406A2 BR 112014028406 A2 BR112014028406 A2 BR 112014028406A2 BR 112014028406 A BR112014028406 A BR 112014028406A BR 112014028406 A BR112014028406 A BR 112014028406A BR 112014028406 A2 BR112014028406 A2 BR 112014028406A2
Authority
BR
Brazil
Prior art keywords
pyrazole derivatives
lpar5 antagonists
lpar5
antagonists
pyrazole
Prior art date
Application number
BR112014028406A
Other languages
English (en)
Portuguese (pt)
Inventor
Evers Andreas
Kozian Detlef
Nazarè Marc
Czechtizky Werngard
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112014028406A2 publication Critical patent/BR112014028406A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112014028406A 2012-05-18 2013-05-16 derivados de pirazol e uso dos mesmos como antagonistas de lpar5. BR112014028406A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305552 2012-05-18
PCT/EP2013/060171 WO2013171317A1 (en) 2012-05-18 2013-05-16 Pyrazole derivatives and their use as lpar5 antagonists

Publications (1)

Publication Number Publication Date
BR112014028406A2 true BR112014028406A2 (pt) 2017-06-27

Family

ID=48446368

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028406A BR112014028406A2 (pt) 2012-05-18 2013-05-16 derivados de pirazol e uso dos mesmos como antagonistas de lpar5.

Country Status (22)

Country Link
US (1) US9346762B2 (cg-RX-API-DMAC7.html)
EP (1) EP2882715B1 (cg-RX-API-DMAC7.html)
JP (1) JP6257596B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150010973A (cg-RX-API-DMAC7.html)
CN (1) CN104302625B (cg-RX-API-DMAC7.html)
AU (1) AU2013261718B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014028406A2 (cg-RX-API-DMAC7.html)
CA (1) CA2871542A1 (cg-RX-API-DMAC7.html)
CY (1) CY1118618T1 (cg-RX-API-DMAC7.html)
DK (1) DK2882715T3 (cg-RX-API-DMAC7.html)
ES (1) ES2612205T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170098T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032890T2 (cg-RX-API-DMAC7.html)
IL (1) IL235221A (cg-RX-API-DMAC7.html)
LT (1) LT2882715T (cg-RX-API-DMAC7.html)
MX (1) MX347615B (cg-RX-API-DMAC7.html)
PL (1) PL2882715T3 (cg-RX-API-DMAC7.html)
PT (1) PT2882715T (cg-RX-API-DMAC7.html)
RU (1) RU2645344C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201407210SA (cg-RX-API-DMAC7.html)
SI (1) SI2882715T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013171317A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521183A (ja) 2012-05-18 2015-07-27 サノフイ ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用
AU2016277126A1 (en) * 2015-06-12 2017-12-14 Vettore, LLC MCT4 inhibitors for treating disease
BR112019011825A2 (pt) 2016-12-12 2019-10-22 Vettore, LLC composto, enantiômero isolado, composição farmacêutica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em uma amostra biológica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em relação ao transportador de monocarboxilato mct1, ou um mutante do mesmo, em um paciente, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 em um sujeito que necessite do mesmo, uso de um composto e método para obter um efeito em um paciente
KR20220077140A (ko) 2019-10-02 2022-06-08 도메인 테라퓨틱스 프로스타글란딘 e2(pge2) ep4 수용체 길항제
WO2024092205A1 (en) * 2022-10-27 2024-05-02 The Trustees Of Indiana University Inhibition of ship1 as a therapeutic strategy for the treatment of alzheimer's disease
CN119930520B (zh) * 2023-11-03 2026-03-06 中国药科大学 N-芳基吡唑类化合物及其药物组合物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
US7279478B2 (en) 2002-09-04 2007-10-09 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
DK2254869T3 (en) 2008-03-07 2017-09-04 Acraf 1-BENZYL-3-HYDROXYMETHYL INDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40
MX2010009625A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
AU2010224652A1 (en) * 2009-03-19 2011-10-13 Sanofi Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof
BR112012002130A2 (pt) * 2009-08-03 2015-09-15 Aziende Chimique Riunite Angelini Francesco A C R A F S P A processo para a preparação de composto,e, composto intermediário
JP6039559B2 (ja) * 2010-09-02 2016-12-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Lpa受容体アンタゴニストとしてのピラゾロピリジノン誘導体
JP2015521183A (ja) 2012-05-18 2015-07-27 サノフイ ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用

Also Published As

Publication number Publication date
EP2882715A1 (en) 2015-06-17
MX2014014011A (es) 2015-02-12
RU2014151360A (ru) 2016-07-10
AU2013261718A1 (en) 2014-12-18
CN104302625B (zh) 2017-04-19
CN104302625A (zh) 2015-01-21
CY1118618T1 (el) 2017-07-12
US9346762B2 (en) 2016-05-24
AU2013261718B2 (en) 2017-10-19
WO2013171317A1 (en) 2013-11-21
HUE032890T2 (hu) 2017-11-28
PL2882715T3 (pl) 2017-04-28
LT2882715T (lt) 2017-02-10
PT2882715T (pt) 2016-12-30
RU2645344C2 (ru) 2018-02-21
JP2015517514A (ja) 2015-06-22
IL235221A (en) 2016-06-30
CA2871542A1 (en) 2013-11-21
US20150141477A1 (en) 2015-05-21
HRP20170098T1 (hr) 2017-03-24
JP6257596B2 (ja) 2018-01-10
MX347615B (es) 2017-05-04
SI2882715T1 (sl) 2017-03-31
DK2882715T3 (en) 2017-02-13
KR20150010973A (ko) 2015-01-29
EP2882715B1 (en) 2016-11-09
ES2612205T3 (es) 2017-05-12
SG11201407210SA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
FR22C1047I2 (fr) Derives de benzimidazole-proline
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
HUE036750T2 (hu) Alfa-v-béta-6 integrin antagonistákként alkalmazható naftiridin-származékok
CL2015002737A1 (es) 4-amino-6-(heterocíclico) picolinatos y 6-amino-2-(heterocíclico) pirimidina-4-carboxilatos y su uso como herbicidas.
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HRP20181855T1 (hr) Lipidi za formulacije namijenjene unosu terapijskog sredstva
DK2900645T3 (da) Herbicidt aktive 3-phenylisoxazolinderivater
HRP20182046T1 (hr) Uređaj za kuhanje i postupak njegove upotrebe
CO6852094A2 (es) 3-alcoxi-, tioalquilo-y amino-4-amino-picolinatos 6-sustituidos y su uso como herbicidas
EP2970569A4 (en) PERSISTENT CARBENE AND COMPOSITIONS WITH IT
PT2968139T (pt) Plataforma de entrega tópica de microemulsão
CL2015001116A1 (es) Composición y uso de dimeros de alquil cetena hidrogenados.
CO7020919A2 (es) Derivados de tetrahidro-quinazolinona
AR092882A1 (es) 1,2,4-triazin-3,5-dion-6-carboxamidas y su uso como herbicidas
CL2014003283A1 (es) Formulación farmacéutica.
BR112015005562A2 (pt) compostos de aminoisoquinolina, suas composições e uso dos novos compostos como inibidores da proteína quinase.
NL301064I2 (nl) toltrazuril en gleptoferron
EP2842946A4 (en) QUINAZOLINDIONDERIVAT
ES1077714Y (es) Envase de madera
CR20140362A (es) Fenilimidazopirazoles sustituidos y su uso
BR112016011430A2 (pt) agentes anticâncer e preparação dos mesmos.
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
BR112015002661A2 (pt) dispositivo de transporte de passagem superior com pórticos de coluna.
BR112014020372A8 (pt) n-etil-n-fenil-1,2-di-hidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, preparação e utilização do mesmo
BR112014016930A8 (pt) compostos tetrazol-5-il- e triazol-5-il-arila e uso destes como herbicidas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements